Section II · Long-Term Picks

Long-Term Picks

Beaten-down, compounders, re-rates; 1-3 years. Grouped by the thesis type stated in each pick.

Prices as of October 16, 2026 close

Beaten-down

Fair Isaac (FICO)

Medium conviction
$771.19 · Oct 16 close

Maker of the FICO credit score and decisioning/fraud software used by most U.S. lenders.

Thesis
Beaten down: about 39% lower over 3 months, after regulators let lenders use VantageScore on equal terms. Early signs the moat holds: United Wholesale Mortgage will keep pulling FICO on every broker loan. A 15% job cut should protect margins. Shares rebounded 15.5% this week.
Catalyst
Lender adoption news; fiscal Q4 results in early-to-mid November.
Risk
Further mortgage share loss to VantageScore; over $5B of debt.
12-month cases · our estimates
Upside to base: +41.5% · Downside to bear: -16.4%
Bear 13× / Base 22× / Bull 32× on FY27E EPS $49.59 (consensus). 5-yr P/E 23–70× (median 38×); bear compresses to 13× on VantageScore share loss, base at the low end of history.

Sources: Price: Oct 16 close, closing prices from exchange market data · Filings: SEC EDGAR (FICO) · EPS & P/E history: StockAnalysis (FICO, forecast) · All FICO calls →

Read in the Week of October 19, 2026 issue →

Nike (NKE)

Low conviction
$37.13 · Oct 16 close

The world's largest athletic footwear and apparel brand.

Thesis
Deep-value turnaround. It hit a 13-year low after revenue fell 4%, and it has a $2.5B cost plan. If the brand stabilizes, today's price could look cheap in 2-3 years. This is a patient, speculative idea, not a quick trade.
Catalyst
Investor Day Nov 17.
Risk
Analyst targets ($24-33) sit below the price; the cost savings mostly land in 2029-30.
12-month cases · our estimates
Upside to base: +7.7% · Downside to bear: -30.0%
Bear 20× / Base 24× / Bull 32× on EPS $1.31 / $1.66 / $1.66 (consensus). 5-yr P/E 25–37× (median 28×); bear on FY27E $1.31, base/bull on FY28E $1.66 turnaround recovery.

Sources: Price: Oct 16 close, closing prices from exchange market data · Filings: SEC EDGAR (NKE) · EPS & P/E history: StockAnalysis (NKE, forecast) · All NKE calls →

Read in the Week of October 19, 2026 issue →

Compounders

Taiwan Semiconductor (TSM)

High conviction
$412.61 · Oct 16 close

The world's largest contract chipmaker; it builds the leading-edge chips for Nvidia, Apple, AMD and others.

Thesis
Quality compounder on sale. Q3 revenue rose 50.9% year over year with a 66.4% gross margin, and Q4 guidance ($52.3-54.3B) points higher. Yet the shares are down about 15% from the $487.47 high in the AI sell-off.
Catalyst
AI chip demand and TSMC's monthly sales reports.
Risk
AI spending pullback, Taiwan geopolitics.
12-month cases · our estimates
Upside to base: +22.1% · Downside to bear: -11.3%
Bear 16× / Base 22× / Bull 27× on FY27E EPS $22.90 (consensus). 5-yr P/E 12–27× (median 24×). FY27E ADR EPS ~$22.90 = FY26E ~$16.97 (implied by 24.3× forward P/E) × 1.35 consensus growth.

Sources: Price: Oct 16 close, closing prices from exchange market data · Filings: SEC EDGAR (TSM) · EPS & P/E history: StockAnalysis (TSM, forecast) · EPS & P/E history: StockAnalysis (TSM, ratios) · All TSM calls →

Read in the Week of October 19, 2026 issue →

Microsoft (MSFT)

Medium conviction
$529.05 · Oct 16 close

Software and cloud leader (Azure, Office 365, Windows), and a major AI platform.

Thesis
Durable compounder with recurring revenue and huge cash flow; buy on weakness during the AI-trade wobble. It is about 4% below its recent $551 high.
Catalyst
Fiscal Q1 earnings Oct 28 (Azure growth, AI revenue, capex).
Risk
Fiscal 2026 capex was about $175B and rising; investors may punish more spending.
12-month cases · our estimates
Upside to base: +12.1% · Downside to bear: -10.2%
Bear 24× / Base 30× / Bull 35× on FY27E EPS $19.78 (consensus). 5-yr P/E 20–35× (median ~32×); bear assumes AI-capex de-rating.

Sources: Price: Oct 16 close, closing prices from exchange market data · Filings: SEC EDGAR (MSFT) · EPS & P/E history: StockAnalysis (MSFT, forecast) · All MSFT calls →

Read in the Week of October 19, 2026 issue →

Re-rates

Humana (HUM)

Medium conviction
$413.16 · Oct 16 close

A leading Medicare Advantage insurer serving seniors.

Thesis
Re-rate story. 95% of members will be in 4-star-or-better plans for 2027, up from 20% for 2026, which Evercore estimates could bring about $4.8B in 2028 bonus payments. The stock is about 9% off its $456.50 high.
Catalyst
Q3 results Nov 6; 2027 enrollment and pricing.
Risk
Already priced richly (about 25x forward earnings by one estimate); Medicare policy risk.
12-month cases · our estimates
Upside to base: +3.3% · Downside to bear: -33.9%
Bear 16× / Base 25× / Bull 30× on FY27E EPS $17.08 (consensus). 5-yr P/E 15–21×; base/bull above range because FY27E EPS is still depressed and the 2028 star-rating bonus is not yet in EPS.

Sources: Price: Oct 16 close, closing prices from exchange market data · Filings: SEC EDGAR (HUM) · EPS & P/E history: StockAnalysis (HUM, forecast) · All HUM calls →

Read in the Week of October 19, 2026 issue →